Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: Results from the Swedish Mortality Registry

JAMA Neurology

Volumn 71, Issue 4, 2014, Pages 476-483

  Skillbäck, Tobias ^a   Rosén, Christoffer ^a   Asztely, Fredrik ^b   Mattsson, Niklas ^a,c,d   Blennow, Kaj ^a   Zetterberg, Henrik ^a,e  

^a Institute of Clinical Neuroscience   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NEUROCHEMISTRY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TIME OF DEATH; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; CREUTZFELDT-JAKOB SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHOSPHORYLATION; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWEDEN; TAU PROTEINS;

EID: 84899030180     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.6455     Document Type: Article

References (33)

1. Kamtchum Tatuene J, Vargas MI, Burkhardt K, Chofflon M. Illustrating the relevance of updated diagnostic criteria for sporadic Creutzfeldt-Jakob disease: A teaching neurocase [published online August 28, 2013]. BMJ Case Rep. doi:10.1136 /bcr-2013-010061.
2. Mader EC, Jr, El-Abassi R, Villemarette-Pittman NR, Santana-Gould L, Olejniczak PW, England JD. Sporadic Creutzfeldt-Jakob disease with focal findings: caveats to current diagnostic criteria. Neurol Int. 2013;5(1):e1. doi:10.4081/ni.2013.e1.
3. Schröter A, Zerr I, Henkel K, Tschampa HJ, Finkenstaedt M, Poser S. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch Neurol. 2000;57(12): 1751-1757.
4. Steinhoff BJ, Räcker S, Herrendorf G, et al. Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol. 1996;53(2): 162-166.
5. Newey CR, Sarwal A, Wisco D, Alam S, Lederman RJ. Variability in diagnosing Creutzfeldt-Jakob disease using standard and proposed diagnostic criteria. J Neuroimaging. 2013;23(1): 58-63.
6. Tagliapietra M, Zanusso G, Fiorini M, et al. Accuracy of diagnostic criteria for sporadic Creutzfeldt-Jakob disease among rapidly progressive dementia. J Alzheimers Dis. 2013;34(1): 231-238.
7. Geschwind MD, Martindale J, Miller D, et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol. 2003;60(6): 813-816. (Pubitemid 36705966)
8. Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012;79(14): 1499-1506.
9. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3): 131-144.
10. Blennow K, Johansson A, Zetterberg H. Diagnostic value of 14-3-3β immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. Int J Mol Med. 2005;16(6): 1147-1149.
11. Baldeiras IE, Ribeiro MH, Pacheco P, et al. Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients. J Neurol. 2009;256(9): 1540-1550.
12. Riemenschneider M, Wagenpfeil S, Vanderstichele H, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry. 2003;8(3): 343-347. (Pubitemid 36712928)
13. Skinningsrud A, Stenset V, Gundersen AS, Fladby T. Cerebrospinal fluid markers in Creutzfeldt-Jakob disease. Cerebrospinal Fluid Res. 2008;5:14. doi:10.1186/1743-8454-5-14.
14. Bahl JM, Heegaard NH, Falkenhorst G, et al. The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease. Neurobiol Aging. 2009;30(11): 1834-1841.
15. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26(3): 231-245. (Pubitemid 26002016)
16. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285(1): 49-52. (Pubitemid 30224621)
17. Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2006;67(4): 637-643. (Pubitemid 44273611)
18. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2002;58(2): 192-197. (Pubitemid 34084207)
19. Davidson M. The interpretation of diagnostic test: A primer for physiotherapists. Aust J Physiother. 2002;48(3): 227-232. (Pubitemid 35021639)
20. Barry HC, Ebell MH. Test characteristics and decision rules. Endocrinol Metab Clin North Am. 1997;26(1): 45-65. (Pubitemid 27123894)
21. World Health Organization. Global Surveillance, Diagnosis and Therapy of Human Transmissible Spongiform Encephalopathies: Report of a WHO Consultation. Geneva, Switzerland:World Health Organization; 1998.
22. UCSF Memory and Aging Center. CJD Diagnostic Criteria. San Francisco, CA: University of San Francisco; 2013.
23. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(pt 10): 2659-2668.
24. Jadav R, Sinha S, Nagarathna S, et al. Carcinomatous meningitis: yet another cause for rapidly progressive dementia and triphasic waves in electroencephalograph! J Neurosci Rural Pract. 2012;3(2): 207-209.
25. Matsuo K, Saburi M, Ishikawa H, et al. Sjögren syndrome presenting with encephalopathy mimicking Creutzfeldt-Jakob disease. J Neurol Sci. 2013;326(1-2): 100-103.
26. Shiga Y, Miyazawa K, Sato S, et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology. 2004;63(3): 443-449. (Pubitemid 39031372)
27. Beaudry P, Cohen P, Brandel JP, et al. 14-3-3 Protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord. 1999;10(1): 40-46. (Pubitemid 28567041)
28. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med. 1996;335(13): 924-930. (Pubitemid 26314445)
29. Satoh J, Kurohara K, Yukitake M, Kuroda Y. The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur Neurol. 1999;41(4): 216-225. (Pubitemid 29241610)
30. Geschwind MD, Shu H, Haman A, Sejvar JJ, Miller BL. Rapidly progressive dementia. Ann Neurol. 2008;64(1): 97-108.
31. Kong A, Kleinig T, Van derVliet A, et al.MRI of sporadic Creutzfeldt-Jakob disease. J Med Imaging Radiat Oncol. 2008;52(4): 318-324.
32. van Harten AC, Kester MI, Visser PJ, et al. Tau and p-tau as CSF biomarkers in dementia: ameta-analysis. Clin Chem Lab Med. 2011;49(3): 353-366.
33. Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2003;74(9): 1210-1214.